Key Takeaway: 4D Molecular Therapeutics has announced the acquisition of an eye disease asset from a subsidiary of Fortress Biotech. This move is part of 4DMT's strategy to enhance its product offerings in the ophthalmology sector. The acquisition reflects the company's commitment to addressing unmet needs in eye disease treatments.
Price reaction · baseline $15.56 (2023-09-15 close) · 4 other FDMT headline(s) in the window, move may be shared
day 0 close
-0.3%
Market Sentiment Analysis
POSITIVE FACTORS
4D Molecular Therapeutics expands its portfolio with a new asset.
The acquisition signifies growth and potential in eye disease treatments.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
Tyler Patchen
News Reporter
California-based biotech 4D Molecular Therapeutics (4DMT) will be acquiring the rights to an asset from a company under the Fortress Biotech umbrella.
On Monday, 4DMT …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Frequently Asked Questions
What company did 4D Molecular Therapeutics acquire from?
4D Molecular Therapeutics acquired the asset from a subsidiary of Fortress Biotech.
What type of asset is being acquired?
The asset pertains to treatments for eye diseases.